Rybelsus, the first and only ORAL GLP-1 agonisant, has been recognized again
-
Last Update: 2020-07-13
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Novo Nordisk's type 2diabetesdrug, the oral GLP-1 agonisant Rybelsus, has been approved for sale in JapanJapan's Ministry of Health, Labour (MHLW) approval was approved by the FDA in October last yearand in February by the European UnionRybelsus is by far the first and only oral drug for GLP-1 agonistsapproval is based on data from the PIONEER clinical trial, which was conducted among 9,500 subjects, including 1,300 Japanese patientsIn the study, Rybelsus, which controlled blood sugar once a day, was equivalent to Trulicity once a week, while the daily dose of 14 mg was better than Trulicity and Victoza, which were injected once a dayNew data from, reported at the American Diabetes Association meeting earlier this month, show that Rybelsus is better at reducinglow blood sugarand weight in people with type 2 diabetes, ahead of Merck's oral DPP-4 inhibitor Januvia, Bollinger Ingehan and Lilly's SGLT2 drosiance and VictozaIn a recent report, Johan Unnerus, an analyst at Pareto Securities, predicted that Rybelsus would generate more than $5 billion in revenue by 2026
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
